Pacira BioSciences (PCRX) FY2016 results: revenue $276 million, up 11.0% on the year
Pacira BioSciences, Inc. (PCRX) reported revenue of $276 million for fiscal 2016, the year ended 31 December 2016, up 11.0% on the year before. Net income was -$38 million, and diluted earnings per share $-1.02. The figures are the company's own, from the 10-K it filed with the SEC on 1 March 2017.
Revenue
$276 million
+11.0% on the year
FY2009FY2016
Operating margin
-11.6%
3.8% a year earlier
FY2009FY2016
Net income
-$38 million
FY2009FY2016
Diluted EPS
-$1.02
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
276
249
198
+11.0%
Cost of revenue
110
71.8
77.4
+53.3%
Gross profit
166
177
120
-6.1%
Gross margin
60.2%
71.1%
60.8%
Research and development
45.7
28.7
18.7
+59.4%
Selling, general and administrative
153
139
107
+9.8%
Operating income
-32.0
9.5
-5.2
Operating margin
-11.6%
3.8%
-2.6%
Interest expense
7.1
7.7
8.3
-8.6%
Pre-tax income
-37.8
2.1
-13.5
Income tax
0.1
0.3
0.2
-60.2%
Effective tax rate
n/a
12.5%
n/a
Net income
-37.9
1.9
-13.7
Net margin
-13.7%
0.7%
-6.9%
Diluted EPS
-$1.02
$0.04
-$0.39
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
33.5
28.0
n/a
+19.4%
Capital expenditure
24.7
40.3
23.0
-38.7%
Free cash flow
8.7
-12.3
n/a
Free cash flow margin
3.2%
-4.9%
n/a
Depreciation and amortisation
12.9
11.5
10.0
+12.6%
Share-based compensation
31.2
33.4
24.8
-6.4%
Diluted shares, weighted
37m
41m
35m
-9.8%
Shares outstanding at period end
37m
37m
36m
+1.7%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
219
218
171
+0.3%
Debt
109
104
103
+4.5%
Other liabilities
63.8
65.3
51.8
-2.4%
Total liabilities and equity
391
388
326
+1.0%
Fixed assets
101
90.3
60.6
+11.8%
Goodwill
46.7
30.9
23.8
+51.4%
Intangible assets
0.0
0.1
0.4
Investments
137
115
144
+18.4%
Cash and equivalents
35.9
57.0
37.5
-36.9%
Receivables
29.9
25.9
22.4
+15.8%
Inventory
31.3
61.6
29.3
-49.3%
Other assets
9.9
6.5
8.6
+51.8%
Total assets
391
388
326
+1.0%
10-K for the year ended 31 December 2016, filed 1 March 2017: the filing.